Dewpoint Therapeutics
Dean has worked for over 12 years in the life sciences industry. Recently, Dean led the Controllership functions of both AskBio, which was sold to Bayer AG in December 2020, and Precision BioSciences, which completed a $146M IPO in 2019. Prior to that, Dean worked in corporate finance for MedImmune, Cisco Systems, 3Com, and HP. He began his career as a CPA and holds degrees from Babson College and Bentley University.
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.